Exosomal circular RNAs as drivers of temozolomide resistance in glioblastoma: Mechanisms and implications

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Glioblastoma (GBM) is a highly malignant brain tumor with limited therapeutic success.
• Resistance to temozolomide (TMZ), a standard GBM treatment, is a major clinical challenge.
• Noncoding RNAs, particularly circular RNAs (circRNAs), are increasingly recognized for their roles in GBM pathogenesis and drug resistance.

Purpose of the Study:

• To review the role of exosomal circRNAs in modulating TMZ resistance in GBM.
• To explore the potential of exosomal circRNAs as diagnostic and prognostic biomarkers for GBM.
• To enhance understanding of the complex mechanisms underlying TMZ resistance in GBM.

Main Methods:

• Literature review focusing on circRNAs, exosomes, and TMZ resistance in GBM.
• Analysis of molecular pathways involving specific exosomal circRNAs (e.g., circASAP1, circ-HIPK3).
• Evaluation of the biomarker potential of exosomal circRNAs in liquid biopsies.

Main Results:

• Exosomal circRNAs can act as microRNA sponges or encode peptides, influencing GBM development and TMZ resistance.
• Specific exosomal circRNAs, like circASAP1 and circ-HIPK3, mediate TMZ resistance through distinct molecular pathways.
• Exosomal circRNAs facilitate intercellular communication, propagating drug resistance within the GBM microenvironment.

Conclusions:

• Exosomal circRNAs are critical players in GBM's resistance to TMZ, offering novel therapeutic targets.
• Exosomal circRNAs hold significant potential as non-invasive biomarkers for GBM diagnosis, prognosis, and treatment monitoring via liquid biopsies.
• Further research into exosomal circRNAs can unravel complex resistance mechanisms and guide personalized GBM therapy.